Genflow Biosciences is at the forefront of biotechnology, focusing on innovative therapeutic approaches aimed at slowing the aging process in both humans and dogs. The company's lead compound, GF-1002, utilizes a centenarian variant of the SIRT6 gene, which has shown promising preclinical results. This gene therapy aims to enhance healthspan and lifespan by addressing the underlying mechanisms of aging. Genflow's research includes pioneering clinical trials, such as the Phase I/II trial for Werner Syndrome, which serves as a model for studying premature aging, and the trial for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a chronic liver condition with significant unmet medical needs.

The company is leveraging advancements in biotechnology to explore gene infusion therapy as a means to combat aging and chronic diseases. By understanding the human genome and the role of genes like SIRT6, Genflow aims to develop strategies that could potentially add years to healthy living. Their approach is not only about extending lifespan but also about improving the quality of life by reducing the burden of age-related diseases. With a clear regulatory pathway for their therapies, Genflow is positioned to make significant contributions to the field of longevity and health improvement.

United Kingdom

Genflow Biosciences plc (LON:GENF) (OTCQB:GENFF) is a UK-based biotech company with R&D facilities in Belgium and a U.S. office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs.

The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results.

Managed by an experienced team with decades of experience in the pharmaceutical and biotechnology sectors, the company is optimistic that development programs will continue at pace in the next 24 months.


Genflow Biosciences

Company Details